billHR740•Event Wednesday, July 23, 2025Analyzed

Veterans’ ACCESS Act of 2025

Bullish

Impact5/10

UnitedHealth Group ($UNH)Humana ($HUM)Molina Healthcare ($MOH)Cigna Group ($CI)CVS Health ($CVS)Healthcare

Summary

The Veterans' ACCESS Act of 2025 (HR740) has cleared committee and awaits floor action, expanding the Veterans Community Care Program to mandate VA referrals to private providers. Major managed care organizations (UNH, HUM, MOH, CI, CVS) are positioned to capture increased patient volume, reflected in strong 7-day and 30-day price gains. This bill authorizes policy changes but does not appropriate funds — actual spending depends on subsequent appropriations.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.The Veterans' ACCESS Act expands statutory access standards for private care referrals from the VA, directly benefiting managed care organizations.
2.All five tickers (UNH, HUM, MOH, CI, CVS) show strong 30-day gains (8.76% to 41.6%), with MOH leading at +38.37% 30-day and +21.22% 7-day.
3.The bill is an authorization, not an appropriation — actual revenue impact depends on future appropriations bills funding the increased claims volume.
4.Bipartisan sponsorship (83 cosponsors) and committee chairman lead sponsor indicate strong legislative momentum toward passage.

Market Implications

The managed care sector is experiencing a clear legislative catalyst from the VCCP expansion. Molina Healthcare's +21.22% 7-day gain reflects its pure-play government-sponsored care model and geographic concentration in high-veteran-population states, making it the highest-beta play. UnitedHealth Group and Humana show strong but less extreme gains, reflecting their larger, more diversified revenue bases. Cigna and CVS (Aetna) also benefit but have relatively lower exposure to VA-referred volume as a share of total revenue. Investors should monitor floor action timing and any CBO score that quantifies the expected cost increase.

Full Analysis

What happened: The Veterans' ACCESS Act of 2025 (HR740) was ordered to be reported (amended) out of the House Committee on Veterans' Affairs on July 23, 2025, by voice vote. The bill currently awaits floor action in the 119th Congress. It establishes statutory access standards for the Veterans Community Care Program, requiring the VA to notify veterans of eligibility within two business days and extending claims submission deadlines for healthcare providers. A companion bill (S275) is progressing in the Senate. The money trail: This bill is an authorization bill — it expands the policy framework for private care referrals but does not appropriate specific dollar amounts. Actual funding for the increased volume of community care claims will require future appropriations bills. The Congressional Budget Office has not yet released a cost estimate for this specific amendment. However, the VCCP already processes millions of claims annually; expanding statutory access standards will increase utilization. Structural winners and losers: The direct beneficiaries are private managed care organizations and healthcare providers with networks capable of absorbing VA-referred patients. UnitedHealth Group (UNH), Humana (HUM), Molina Healthcare (MOH), Cigna (CI), and CVS Health (CVS) are the largest publicly traded managed care organizations positioned to handle increased claim volume. Community hospitals and independent physician groups also benefit indirectly. The VA's own direct-care facilities may see reduced patient load. Real market data analysis: All five tickers show strong positive momentum over the past 7 and 30 days, reflecting broad investor anticipation. UNH: $366.77, +3.75% 7-day, +41.6% 30-day. HUM: $229.72, +5.67% 7-day, +35.86% 30-day. MOH: $185.46, +21.22% 7-day, +38.37% 30-day. CI: $284.92, +3.72% 7-day, +8.76% 30-day. CVS: $80.98, +5.95% 7-day, +15.55% 30-day. Molina's outsized 21.22% 7-day gain suggests the highest beta to this legislative catalyst among the group. Timeline: HR740 awaits floor action in the House. A companion bill (S275) has also been ordered to be reported favorably in the Senate Veterans' Affairs Committee. The bill's lead sponsor is Rep. Mike Bost (R-IL), chairman of the House Veterans' Affairs Committee, which provides strong leadership momentum. Passage probability is elevated by bipartisan cosponsorship (83 cosponsors) and committee approval. Floor votes could occur in Q3 or Q4 2025.

Market Impact Score

5/10

Minimal ImpactModerateMajor Market Event

Connected Signals

Matched on shared policy language across AI analyses, with ticker & timing weight

BillBullish

Association Health Plans Act

Shared tickers: $UNH, $CI, $HUM, $MOH, $CVS$UNH · $CI · $HUM +3

6/10

BillBearish

Medicare for All Act

Shared tickers: $UNH, $CVS, $HUM, $CI, $MOH$UNH · $CVS · $HUM +7

5/10

BillBullish

I CAN Act

Shared tickers: $UNH, $HUM, $MOH, $CVS$UNH · $HUM · $MOH +2

7/10

BillBearish

Putting Patients First Healthcare Freedom Act

Shared tickers: $UNH, $HUM, $CVS, $MOH$UNH · $HUM · $CVS +2

6/10

BillNeutral

Supporting Healthy Moms and Babies Act

Shared tickers: $UNH, $CI, $HUM, $CVS$UNH · $CI · $HUM +5

5/10

BillBullish

Improving Seniors’ Timely Access to Care Act of 2025

Shared tickers: $UNH, $HUM, $CVS$ORCL · $UNH · $ELV +2

7/10

BillBearish

To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.

Shared tickers: $CVS, $CI, $UNH$CVS · $CI · $ELV +1

6/10

BillBearish

Lowering Drug Costs for American Families Act

Shared tickers: $UNH, $CVS, $HUM$JNJ · $PFE · $MRK +5

6/10

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.

$CMPS $MNMD $GHRS $ATAI $CYBN $NUMI

8/10Source